Lilly is planning to merge its U.S. and international business divisions after a top executive’s retirement, according to reporting on corporate restructuring. The move comes as the company navigates ongoing portfolio and operating-model changes tied to its pipeline and downstream manufacturing and commercial footprint. In parallel, Novartis is writing off part of its Avidity deal, signaling continuing portfolio and risk adjustments following the transaction. Separately, reporting also references progress toward a cancer immunotherapy candidate by Astellas, pointing to ongoing deal churn in oncology assets.